glp-1 agonists for type 2 diabetes Clinical Focus on in Mellitus VisualAbstract: Glucagon-like peptide 1 receptor
Description
*Livongo is now part of Teladoc Health, and we are in a brand transition phase
Individuals who experience nausea from GLP-1 medications tend to be more common when first starting treatment or increasing the dosage
Pancreatic cancer has drawn particular scrutiny due to its high fatality rate and some early observational reports suggesting elevated risk with incretin-based therapies (Del Prato et al., 2021
J Neurosci Res (2011) 89:4819
MeSH terms searched included SGLT2 or sodium glucose transport proteins, GLP-1 or glucagon-like peptides, and T2DM
